Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease

Study information

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-1-25

study design

randomized controlled trial

Citation

PMID PubMed identifier for scientific articles.

36198385

DOI Digital object identifier for electronic documents.

10.1016/j.anaerobe.2022.102652

URI

Authors

Bamola VD, Dubey D, Samanta P, Kedia S, Ahuja V, Madempudi RS, Neelamraju J, Chaudhry R

Journal

Anaerobe

Year

2022

Keywords:

Bacillus clausii UBBC-07, Cytokines, Gut microbiome, IBD, Probiotic

OBJECTIVE: To assess the effect of a probiotic strain Bacillus clausii UBBC-07 on gut microbiota and cytokines in IBD patients. METHOD: Patients were randomly allocated to either placebo or probiotic Bacillus clausii UBBC-07 for four weeks along with the standard medical treatment (SMT). Enrolled patients were evaluated before and after intervention for presence of the given probiotic, change in gut microbiota, change in serum cytokines, serotonin and dopamine, symptoms of disease, physical, behavioral and psychological parameters. RESULTS: Probiotic strain Bacillus clausii UBBC-07 showed good survival in IBD patients in the treatment group (p < 0.01) without any reported adverse event. Metagenomic analysis showed that the given probiotic strain was able to modulate the gut microbiota in treated group. Phylum Firmicutes was increased and phylum Bacteroidetes was decreased in the probiotic treated group. A significant increase was observed in the abundance of anaerobic bacterial genera Lactobacillus, Bifidobacterium and Faecalibacterium in the probiotic treated group (p < 0.01) as compared to placebo group. Significant increase was observed in IL-10 (p < 0.05) and variable decrease in the secretion of IL-1β, TNF- α, IL-6, IL -17 and IL -23 in probiotic treated group. In the treatment group a significant decrease in the symptoms of IBD and improvement in the psychological parameter to various degrees was noted. CONCLUSION: These results indicated that probiotic strain B clausii UBBC-07 affected the gut microbiota and cytokine secretion and shown efficacy in IBD patients.

Experiment 1

Edit History Delete

Flag for review

Your review change was submittedDuplicate this Experiment Add a new Signature

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-1-25

Curated date: 2023/03/11

Curator: Brian

Revision editor(s): Brian, Atrayees, Aiyshaaaa, Peace Sandy, ChiomaBlessing, Folakunmi

Subjects

Location of subjects: India

Host species Species from which microbiome was sampled. Contact us to have more species added.: Homo sapiens

Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology: Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces

Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology: Treatment Treatment,treatment

Group 0 name Corresponds to the control (unexposed) group for case-control studies: Placebo group before intervention/treatment

Group 1 name Corresponds to the case (exposed) group for case-control studies: Bacillus clausii UBBC-07 group after intervention/treatment

Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group: Patients who were treated with Bacillus clausii UBBC-07 and evaluated after treatment/intervention for the effect of the probiotic on gut microbiota. Patients were of either sex, clinically diagnosed with Ulcerative Colitis or Crohn's Disease, and between 18 and 60 years.

Group 0 sample size Number of subjects in the control (unexposed) group: 54

Group 1 sample size Number of subjects in the case (exposed) group: 54

Lab analysis

Sequencing type: 16S

16S variable region One or more hypervariable region(s) of the bacterial 16S gene: V3-V4

Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance: Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).: relative abundances

Statistical test: Kruskall-Wallis

Significance threshold p-value or FDR threshold used for differential abundance testing (if any): 0.01

MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?: No

Signature 1

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-1-25

Curated date: 2023/10/17

Curator: Folakunmi

Revision editor(s): Folakunmi, ChiomaBlessing

Source: Results within text: Page 4, under subheading "Metagenomic analysis"

Description: Differentially abundant taxa in the UC patients of the Bacillus clausii UBBC-07 group post intervention/ treatment compared to placebo groups post intervention/ treatment

Abundance in Group 1: increased abundance in Bacillus clausii UBBC-07 group after intervention/treatment

NCBI	Quality Control	Links
Bacilli
Bacillota
Erysipelotrichales
Faecalibacterium
Lactobacillales
Lactobacillus
Bifidobacterium

Revision editor(s): Folakunmi, ChiomaBlessing

Signature 2

Edit History Delete

Flag for review

Your review change was submitted

Reviewed Marked as Reviewed by ChiomaBlessing on 2024-1-25

Curated date: 2023/10/18

Curator: Folakunmi

Revision editor(s): Folakunmi, ChiomaBlessing

Source: Results within text: Page 4, under subheading "Metagenomic analysis."

Description: Differentially abundant taxa in the UC patients of the Bacillus clausii UBBC-07 group post intervention/ treatment compared to placebo groups post intervention/ treatment

Abundance in Group 1: decreased abundance in Bacillus clausii UBBC-07 group after intervention/treatment

NCBI	Quality Control	Links
Bacteroidia
Selenomonadales

Revision editor(s): Folakunmi, ChiomaBlessing